每经AI快讯，康龙化成(03759.HK)再跌超3%，截至发稿跌3.41%，报22.12港元，成交额1.13亿港元。 ...

Core Viewpoint - Kanglong Chemical (03759) has seen a decline of over 3%, currently trading at HKD 22.12, with a transaction volume of HKD 113 million [1] Group 1: Fundraising and Stock Issuance - On January 15, Kanglong Chemical announced a plan to issue nearly 58.44 million new H-shares at a price of HKD 22.82 per share, representing a discount of approximately 8.5% compared to the closing price on January 14 [1] - The net proceeds from this fundraising are expected to be around HKD 1.319 billion, with approximately 70% allocated for project construction to enhance laboratory service facilities, drug process development, and production capacity [1] Group 2: Earnings Forecast - Kanglong Chemical recently released an earnings forecast, projecting a net profit attributable to shareholders for 2025 to be between HKD 1.614 billion and HKD 1.686 billion, indicating a year-on-year decline of 6% to 10% [1] - During the reporting period, the company's operating revenue is expected to grow by 13% to 16%, while the net profit after excluding non-recurring gains and losses is anticipated to increase by 36% to 41% year-on-year [1]

消息面上，1月15日，康龙化成发布公告，拟配售近5844.08万股新H股，配售价每股22.82港元，较1月 14日收市价折让约8.5%，募资所得款项净额约13.19亿港元，其中约70%将用于公司的项目建设，以加 强实验室服务设施、药物工艺开发及生产设施的能力及产能。 康龙化成（300759）(03759)再跌超3%，截至发稿，跌3.41%，报22.12港元，成交额1.13亿港元。 此外，康龙化成近日公布业绩预告，预计2025年归属于上市公司股东的净利润为16.14亿元-16.86亿元， 比上年同期下降6%-10%。报告期内，公司营业收入同比增长13%-16%，扣除非经常性损益后的净利润 同比增长36%-41%。 ...

Group 1 - The stock of Kanglong Chemical (03759.HK) has dropped over 3%, currently down 3.44% at HKD 23.04 [2] - The trading volume reached HKD 157 million [2]

Core Viewpoint - Kanglong Chemical (03759) has seen a decline of over 3%, currently trading at HKD 23.04 with a transaction volume of HKD 157 million [1] Group 1: Company Announcement - Kanglong Chemical announced a proposed placement of approximately 58.44 million new H-shares, representing about 3.19% of the company's enlarged total issued shares and approximately 16.57% of the total issued H-shares [1] - The placement price is set at HKD 22.82 per share, reflecting a discount of approximately 8.5% compared to the closing price on January 14 [1] Group 2: Use of Proceeds - The company expects total gross proceeds and net proceeds from the placement to be approximately HKD 1.334 billion and HKD 1.319 billion, respectively [1] - Approximately 70% of the proceeds will be used for project construction to enhance laboratory service facilities, drug process development, and production capacity [1] - About 10% of the proceeds will be allocated to repay bank loans and other borrowings to optimize the capital structure, while the remaining 20% will be used to supplement working capital and for other general purposes [1]

Core Viewpoint - 康龙化成 announced a placement of approximately 58.44 million new H-shares, representing about 3.19% of the company's expanded total issued shares and about 16.57% of the total issued H-shares, at a price of HKD 22.82 per share, which is an 8.5% discount compared to the closing price on January 14 [1] Group 1 - The company’s stock fell by 3.44% to HKD 23.04, with a trading volume of HKD 157 million [1] - The expected total amount raised from the placement is approximately HKD 13.34 billion, with a net amount of about HKD 13.19 billion [1] - Approximately 70% of the proceeds will be used for project construction to enhance laboratory service facilities, drug process development, and production capacity [1] Group 2 - About 10% of the proceeds will be allocated to repay bank loans and other borrowings to optimize the capital structure [1] - The remaining 20% will be used to supplement working capital and for other general purposes [1]

Core Viewpoint - Kanglong Chemical announced the approval of a proposal to issue new H-shares based on general authorization during the 18th meeting of its third board of directors [1] Group 1 - The board meeting was held on January 15 [1] - The proposal aims to enhance the company's capital structure and support future growth [1]

Group 1 - The company, 康龙化成, experienced a significant decline in its H-shares, dropping by 7.7% [1] - The company plans to issue new H-shares at a discount of 8.5% [1]

Group 1 - The company, 康龙化成 (3759.HK), experienced a significant intraday drop of nearly 8% to HKD 23.02 [1] - The company announced a placement of approximately 58 million new H-shares at a price of HKD 22.82 per share, representing an 8.5% discount to the closing price on Wednesday [1] - The placement shares will account for 3.19% of the total issued shares post-expansion, with the company aiming to raise approximately HKD 1.33 billion for project construction, working capital, and repayment of bank loans and other borrowings [1] Group 2 - The company recently released an earnings forecast, projecting a net profit attributable to shareholders for 2025 to be between RMB 1.614 billion and RMB 1.686 billion, reflecting a year-on-year decline of 6% to 10% [1] - During the reporting period, the company's operating revenue is expected to grow by 13% to 16% year-on-year, while the net profit after excluding non-recurring gains and losses is anticipated to increase by 36% to 41% year-on-year [1]

Core Viewpoint - 康龙化成 (03759) experienced a decline of over 7%, currently trading at 23.18 HKD, with a transaction volume of 27.84 million HKD [1] Group 1: Company Announcement - 康龙化成 announced a proposed placement of approximately 58.44 million new H-shares, representing about 3.19% of the company's enlarged total issued shares and about 16.57% of the total issued H-shares [1] - The placement price is set at 22.82 HKD per share, reflecting a discount of approximately 8.5% compared to the closing price on January 14 [1] Group 2: Use of Proceeds - The company expects to raise approximately 1.334 billion HKD in total proceeds, with a net amount of about 1.319 billion HKD from the placement [1] - Approximately 70% of the proceeds will be allocated to project construction, aimed at enhancing laboratory service facilities, drug process development, and production capacity [1] - About 10% of the proceeds will be used to repay bank loans and other borrowings to optimize the capital structure, while the remaining 20% will be allocated for working capital and other general purposes [1]